Spruce Biosciences, Inc. (SPRB)
| Market Cap | 32.19M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -44.17M |
| Shares Out | 23.49M |
| EPS (ttm) | -1.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,297 |
| Open | 1.31 |
| Previous Close | 1.36 |
| Day's Range | 1.31 - 1.37 |
| 52-Week Range | 1.25 - 15.08 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 9.35 (+582.5%) |
| Earnings Date | May 11, 2022 |
About SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for...
Financial Performance
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price forecast is 9.35, which is an increase of 582.48% from the latest price.
News
Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences to Participate in May Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C.
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences to Participate in March Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
5 Beaten-Down Biotech Bets to Bounce Back in 2022
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk
Penny stocks with high short interest gaining plenty of attention in the stock market today. The post Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk appeared first on Penny Stocks to Bu...
Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now
5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?
Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme...
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
Spruce Biosciences Appoints Mike Grey as Interim CEO
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences Appoints Mike Grey as Interim CEO
Spruce Biosciences to Participate in September Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in September Investor Conferences
Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day
Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary Syndrome
Late-stage biopharmaceutical company Spruce Biosciences Inc (NASDAQ: SRPB) reported financial results for the second quarter ended June 30, 2021 and announced that it has submitted an investigational ne...
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders wit...
Why Earnings Season Could Be Great for Spruce Biosciences (SPRB)
Spruce Biosciences is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates
Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors.
Dr. Ways' Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruce's Goal to Expand Portfolio of Indications for Tildacerfont San Francisco, Calif. ...
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and...
Tildacerfont was Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia (CAH) Data Demonstrated Normalization or Trend to Normalization in Key Hormone Biomarkers